For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 17,595 | -91,930* | 14,142 | 261,499 |
| General and administrative | 17,565 | 9,985* | 13,965 | 12,785 |
| Total operating expenses | 35,160 | -81,945 | 28,107 | 274,284 |
| Gain from operations | -35,160 | 81,945* | -28,107 | -274,284 |
| Interest income | 3,935 | 2,466* | 1,731 | 537 |
| Other income | - | -8,296* | 4,149 | - |
| Change in fair value of warrant liabilities | 188,360 | -2,807,435* | 790,457 | 1,299,922 |
| Total other (expense) income | -184,425 | 2,801,605* | -784,577 | -1,299,385 |
| Net gain | -219,585 | 2,883,549* | -812,684 | -1,573,669 |
| Unrealized (loss) gain on available for sale marketable securities | -747 | 36 | -2 | -9 |
| Total other comprehensive (loss) income | -747 | 36* | -2 | -9 |
| Comprehensive gain | -220,332 | 2,883,584 | -812,686 | -1,573,678 |
| Basic EPS | -5.11 | 292.101 | -121.63 | -12.56 |
| Diluted EPS | -5.11 | 292.101 | -121.63 | -12.56 |
| Basic Average Shares | 43,011,544 | 9,871,866* | 6,681,794 | 125,271,447 |
| Diluted Average Shares | 43,011,544 | 9,871,866* | 6,681,794 | 125,271,447 |
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)